Hemophilia Partnership Opportunities
Dr. Carol Miao ’s lab is focused on developing gene therapy strategies for treating genetic diseases, such as hemophilia, and immunomodulation protocols to overcome immune responses following gene or protein replacement therapy.
- Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets for hemophilia A treatment
- Immunomodulation therapy to prevent or modulate inhibitory antibody responses in hemophilia patients
- Ultrasound-mediated gene delivery for hemophilia treatment